泰乐抗癌增敏口服液联合放射疗法治疗晚期非小细胞肺癌

The clinical study of treating advanced nonsmall-cell lung cancer combining radiotherapy with Taile oral liquid

目的探讨泰乐抗癌增敏口服液(简称泰乐口服液,批准文号931024)对晚期非小细胞肺癌的抗癌作用及放疗增敏作用。方法56例晚期非小细胞肺癌患者随机分为两组:泰乐口服液联合放疗28例(联合组),单纯放疗28例(单放组)。所有患者用60Co外照射,2 Gy/次,1次/d,总剂量84～100 Gy;联合组在放疗中同时口服泰乐口服液,10 ml/次,3次/d,总剂量约1200～1 500 ml。结果联合组总有效率53%,完全缓解率14%,单放组总有效率25%,无完全缓解者。治疗后,两组患者的NK细胞活性均有明显升高。T细胞亚群监视结果显示,治疗后联合组T4升高,T8降低,T4/T8比值升高,较治疗前有显著差异,而单放组T细胞亚群无明显变化。联合组NK细胞活性和T4/T8比值的升高幅度明显大于单放组(P<0.01和<0.05)。治疗中白细胞下降的发生率联合组低于单放组(P<0.01)。结论泰乐口服液对放射治疗晚期非小细胞肺癌具有确切的抗癌增敏作用。

Objective To study the anti-tumor and radiotherapy sensitization of Taile oral liquid（TOL） in combination with radiotherapy for treating advanced non-small cell lung cancer （ ANSCLC ）. Methods Fifty-six patients with ANSCLC were divided into two groups, of which 28 patients were treated by TOL combining with irradiation and 28 patients were treated by irradiation alone. All the patients received the ^60Co external irradiation 2 Gy once a time and once a day for 84 - 100 Gy while the united group took orally TOL 10 ml once a time and three times a day for 1 200 - 1 500 ml. Results The totally effective rate of the united group was 53% and the total remission 14% . The total effective rate of the irradiation group was 25% and there was no one for total remission. After treatment, the NK cytoactive of all the patients was improved obviously. The monitoring results for T cell subgroup showed, in the united group, the T4 raised while T8 lowered and the ratio between T4 and T8 raised but T cell subgroup in the irradiation group had no obvious change. The NK cytoactive and the ratio between T4 and T8 of the patients in the united group obviously exceeded those in the irradiation group（ P 〈0.01 and 〈0.05）. During the treatment, the incidence of the white cell descending in the united group was lower than that in the irradiation group （ P 〈 0.01 ）. Conclusion The results show that the treatment of advanced non-small cell lung cancer with Taile oral liquid has definite the anti-tumor and radiotherapy sensitization.